Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, a

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company mov

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement coverin

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate

$125,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC ("TD

Alector (NASDAQ:ALEC) reported quarterly losses of $(0.21) per share which beat the analyst consensu

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earning

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoin

Wall Street analysts upgraded several stocks, including Cloudflare, Alector, ProPetro, and Atlas Ene

After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a te

Three health-technology names are drawing fresh analyst attention this week as strategic partnership

Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about th

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate

Alector (NASDAQ:ALEC) reported quarterly losses of $(0.34) per share which beat the analyst consensu

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clini

Milestone Pharmaceuticals (NASDAQ: MIST - Get Free Report) and Alector (NASDAQ: ALEC - Get Free Repo

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ

Alector, Inc. (NASDAQ: ALEC - Get Free Report) has been assigned an average rating of "Reduce" from

Alector, Inc. (NASDAQ: ALEC - Get Free Report) was the target of a significant growth in short inter

Alector, Inc. (NASDAQ: ALEC - Get Free Report)'s stock price was up 4.8% during trading on Monday. T

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clini

Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint.

HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers

Alector Pipeline OutlookAlector remains focused on advancing a pipeline of programs designed to trea

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s

Alector (NASDAQ:ALEC) raises FY2025 sales outlook from $5.000 million-$15.000 million to $13.000 mil

Alector (NASDAQ:ALEC) reported quarterly losses of $(0.30) per share which beat the analyst consensu

Mizuho analyst Graig Suvannavejh upgrades Alector (NASDAQ:ALEC) from Neutral to Outperform and ra

-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., ef